Teva Pharmaceutical Industries Limited (TEVA) stock news
The latest Teva Pharmaceutical Industries Limited news and press releases. 1 news stories in the last 24 hours, 2 times its usual daily coverage. TEVA stock report · Market news
Latest news
- David Einhorn Bets on Aluminum in Q3: Here Are His New Stock Picks, Fund Changes Benzinga, Nov 17, 4:36 PM UTC
DME Capital Management LP, founded and led by well-known investor David Einhorn , unveiled its newest third-quarter stock positions and fund changes on Monday. Here are the latest moves. - FDA Clears Teva's Newly Acquired At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder Benzinga, Nov 16, 6:11 PM UTC
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced on Monday that the U.S. Food and Drug Administration (FDA) approved IGALMI (dexmedetomidine) sublingual film for at-home use. - Teva Pharmaceutical Industries Targets Up to $7 Billion in Innovative Drug Revenue by 2030 MarketBeat, Nov 11, 9:12 PM UTC
Teva Pharmaceutical Industries NYSE: TEVA outlined plans to grow its innovative medicines business and advance a pipeline spanning neuroscience, immunology and cancer treatments at its first R&D Day. - Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now? The Motley Fool, Nov 6, 1:48 PM UTC
Teva improved margins significantly. The pharmaceutical company has paid down net debt. - What Teva Pharmaceutical Industries (TEVA) Said on Its Q3 Earnings Call Defense World, Nov 6, 7:17 AM UTC
Teva Pharmaceutical Industries (NYSE: TEVA) reported third-quarter 2026 revenue of approximately $4.4 billion, down 2% from a year earlier, as growth in its innovative medicines portfolio was offset by lower generic-d... - Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock Up Zacks Investment Research, Nov 4, 4:40 PM UTC
Teva's Q3 earnings beat estimates as strong branded drug sales fueled growth, prompting higher 2026 revenue and product sales guidance. - Teva Pharmaceutical Industries Limited (TEVA) Q3 2026 Earnings Call Transcript Seeking Alpha, Nov 3, 9:35 PM UTC
Teva Pharmaceutical Industries Limited ( TEVA ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Christopher Stevo - Senior Vice President of Investor Relations & Competitive Intelligence Richar... - Compared to Estimates, Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Key Metrics Zacks Investment Research, Nov 3, 3:31 PM UTC
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wa... - Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo Reuters, Nov 3, 3:11 PM UTC
Teva Pharm to grow more in 2027 despite US' IRA impact on Austedo - Teva Pharmaceutical Q3 profit gain beats estimates Reuters, Nov 3, 12:29 PM UTC
Teva Pharmaceutical Q3 profit gain beats estimates - Why Is Teva Stock Trading Lower on Monday? Benzinga, Nov 2, 3:01 PM UTC
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), will discontinue its Phase 2 TOPAS-MSA study evaluating emrusolmin in adult patients with multiple system atrophy. - Teva to discontinue mid-stage neurodegenerative disorder study Reuters, Nov 2, 1:18 PM UTC
Teva to discontinue mid-stage neurodegenerative disorder study - Buy, Sell, or Hold? Today’s Top Upgrades and Downgrades: Amazon.com, Coinbase Global, CrowdStrike, FormFactor, GameStop, L3Harris Technologies, Oracle, Reddit, Rivian Automotive, and More 247 Wallst, Nov 2, 1:13 PM UTC
Wall Street analysts are making bold moves this week, with dramatic target price cuts on some high-flying names and surprise upgrades on stocks that took a beating in October. Which calls deserve your attention before... - Teva: I Still See Upside After A Massive Rally Seeking Alpha, Oct 31, 11:22 AM UTC
Teva Pharmaceutical Industries is undergoing a strategic transformation, pivoting from generics to innovative biopharmaceuticals, with a robust new product pipeline. FDA approval of WELTRUZA and several high-potential... - Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years? The Motley Fool, Oct 30, 3:00 PM UTC
Teva's pivot from generic drugs to branded drugs has fueled an 100% surge for shares over the past year. Based on recent results and catalysts, don't rule out a continued, steady move towards higher price levels. - What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q3 Earnings Zacks Investment Research, Oct 29, 2:16 PM UTC
Get a deeper insight into the potential performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates... - Baron Health Care Fund Q3 2026 Top Contributors And Detractors Seeking Alpha, Oct 26, 8:00 AM UTC
TMO's organic growth of 5% exceeded consensus by 200 basis points, and management raised full-year organic growth guidance/. MTD's local-currency sales grew 6%, exceeding prior guidance of 3%. TEVA management raised g... - TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia Zacks Investment Research, Oct 12, 5:10 PM UTC
Teva wins FDA approval for Weltruza, the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia, with a U.S. launch expected soon. - Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript Seeking Alpha, Oct 9, 4:53 PM UTC
Teva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript - FDA Approves Teva's New Once-Monthly Schizophrenia Injection Benzinga, Oct 9, 4:28 PM UTC
The U.S. Food and Drug Administration (FDA) recently approved Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) to market Weltruza, a once-monthly subcutaneous injectable for adult patients with schizophrenia. - Teva Wins FDA Approval for Monthly Schizophrenia Injectable WELTRUZA MarketBeat, Oct 9, 4:02 PM UTC
Teva Pharmaceutical Industries NYSE: TEVA said the U.S. Food and Drug Administration has approved WELTRUZA, a once-monthly subcutaneous long-acting injectable formulation of olanzapine for schizophrenia. - Teva wins FDA approval for monthly schizophrenia injection Weltruza Reuters, Oct 9, 11:17 AM UTC
Teva said on Friday it had received approval from the US Food and Drug Administration for its Weltruza drug for extended-release injectable suspension as the first and only once-monthly subcutaneous injectable ... - Here Are Thursday’s Top Wall Street Analyst Research Calls: BP, Dollar Tree, Exxon Mobil, Lennar, Occidental Petroleum, Rocket Lab, Teva Pharmaceuticals, United Therapeutics, and More 247 Wallst, Oct 1, 12:17 PM UTC
Wall Street analysts reshuffled their bets on energy giants, homebuilders, and emerging space plays on Thursday, and the moves cut in some surprising directions for names investors thought they had figured out. - Teva's Branded Drugs Take Center Stage in Its Growth Strategy Zacks Investment Research, Sep 29, 1:51 PM UTC
Teva's branded drugs are driving stronger growth as Austedo, Ajovy and Uzedy gain momentum and its pipeline of new candidates expands. - Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround The Motley Fool, Sep 29, 9:35 AM UTC
Forecasts call for Teva's branded drug portfolio to bring it $3.7 billion in revenue next year. At the same time, as it pivots toward high-margin drug products, Teva continues to reduce debt and improve its credit rat... - Teva Eyes New Growth Phase After Securing Investment-Grade Ratings Defense World, Sep 24, 9:03 AM UTC
Teva Pharmaceutical Industries (NYSE: TEVA) is planning for greater financial flexibility after receiving investment-grade ratings from all three major credit rating agencies, President and CEO Richard Francis said at... - Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript Seeking Alpha, Sep 23, 1:41 PM UTC
Teva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2026 Transcript - Teva Pharmaceutical Industries Limited (TEVA) Presents at U.S. All Stars Conference Transcript Seeking Alpha, Sep 22, 11:19 AM UTC
Teva Pharmaceutical Industries Limited (TEVA) Presents at U.S. All Stars Conference Transcript - Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline Defense World, Sep 22, 9:03 AM UTC
Teva Pharmaceutical Industries (NYSE: TEVA) Chief Executive Officer Richard Francis said the company has shifted from being viewed primarily as a generics manufacturer toward a biopharmaceutical company with a growing... - Most Active Options Report: FPS, TEVA, AFL Schaeffers Research, Sep 16, 3:53 PM UTC
These three stocks are seeing some of the most unusual options volume today
Press releases
- Teva Announces R&D Leadership Transition; Eric Hughes to Depart the Company GlobeNewsWire, Nov 18, 10:00 PM UTC
Teva's Pivot to Growth Strategy, R&D priorities, and expectations remain unchanged; Company initiates search for successor Teva's Pivot to Growth Strategy, R&D priorities, and expectations remain unchanged; Company in... - Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030 GlobeNewsWire, Nov 11, 12:30 PM UTC
Teva hosts its first R&D Day, sharing pipeline updates and a target of $6–7 billion in innovative medicines revenue by 2030 as a high-velocity biopharma. - Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S. GlobeNewsWire, Nov 3, 10:00 AM UTC
Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO® upon close and infliximab-abda in Q3 2027 Collaboration combines Samsung Bioepis' biosimilar expertise with Teva's commercial capab... - Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline GlobeNewsWire, Oct 27, 12:00 PM UTC
Teva acquires worldwide rights to BXCL501, expanding its neuroscience pipeline with a potential at-home treatment for agitation currently under FDA review - Teva to Host R&D Day on Wednesday, November 11 in New York City GlobeNewsWire, Oct 12, 9:45 PM UTC
TEL AVIV, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will host an R&D Day on Wednesday, November 11, 2026. At the R&D Day, Teva's leader... - Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia GlobeNewsWire, Oct 9, 11:00 AM UTC
WELTRUZA ™ (olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophrenia in adults wi... - Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome GlobeNewsWire, Oct 2, 12:00 PM UTC
PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for ecopipam, a first-in-class investig... - Journal of Child Neurology Publishes Review Highlighting Dopamine's Role in Tourette Syndrome and Ecopipam's Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients GlobeNewsWire, Oct 2, 12:00 PM UTC
PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the Journal of Child Neurology published a ... - Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates Business Wire, Oct 1, 8:30 AM UTC
INCHEON, Korea & TEL AVIV, Israel--(BUSINESS WIRE)-- #Fasenra--Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the companies have entered into a global lice... - TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness GlobeNewsWire, Sep 30, 8:32 PM UTC
TEL AVIV, Israel, Sept. 30, 2026 (GLOBE NEWSWIRE) -- TAPI (Technology & API Services) today announced the appointment of Serge Rogasik as its Chief Executive Officer. - Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab) GlobeNewsWire, Sep 28, 8:00 PM UTC
TEL AVIV, Israel, and PARSIPPANY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved DEGEVM... - Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET GlobeNewsWire, Sep 23, 8:45 PM UTC
TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2026 financia...
Headlines link to their publishers. Research data, not investment advice.